Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $161.62 +2.10%
Revenue Growth %: +26.4%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +26.4%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.63, $0.50 better than the analyst estimate of $1.13. Revenue for the quarter came in at $580 million versus the consensus estimate of $547.1 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
- Lockheed Martin wins $83 million Army missile contract
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
